The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Workforce
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / S.C. Rheumatism Society Benefits from ACR Partnership

S.C. Rheumatism Society Benefits from ACR Partnership

April 6, 2017 • By Gretchen Henkel

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Editor’s note: This article will be the first in a series of articles highlighting the advocacy work done by state and local societies around the country.

You Might Also Like
  • ACR Advocacy at the State Level in 2016
  • The ACR’s Advocacy at State Legislature Level in 2016 Focuses on Biosimilars, Step Therapy
  • New Life for the Michigan Rheumatism Society
Also By This Author
  • Nuts and Bolts of Contract Negotiations for Young Physicians

The South Carolina Rheumatism Society (SCRS) realizes multiple benefits from its association with the ACR, according to Jeffrey G. Lawson, MD, the society’s treasurer. One example of the support offered: A coalition comprising representatives from the SCRS, the ACR, the Arthritis Foundation and other interested

Jeffrey G. Lawson, MD, the South Carolina Rheumatism Society’s treasurer.

stakeholders advocated for the introduction of H.B. 3438, the biosimilars substitution bill sponsored by State Representative Phyllis Henderson. If the bill passes, South Carolina will join its neighbors, Georgia and North Carolina, in rewriting parts of the state’s pharmaceutical code to allow for the substitution of biosimilars for their reference biologics.

H.B. 3438 Benefits & Concerns
Since March 2015, 28 states have taken advantage of the pathway established by the Biologics Price Competition and Innovation Act of 2009, which created an abbreviated approval pathway for biological products that are demonstrated to be highly similar (biosimilar) to or interchangeable with an FDA-approved biological product. The FDA approved the first biosimilar in the United States in March of 2015. But because current South Carolina legislation does not specifically address biosimilars, the ability to substitute them has not been an option, either for rheumatologists or pharmacists. “Having this law in place will allow that [substitution] process to occur,” says Dr. Lawson.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Another key provision of H.B. 3438 would set up specific communications between pharmacists and physicians. Specifically, the bill would require pharmacists to communicate to the prescribing physician within five days when a substitution of an FDA-approved biosimilar for a name-brand biologic has occurred.

In an opinion column to the Greenville Journal on Feb. 12, 2017, Rep. Henderson wrote that the impetus for her sponsorship of the bill was to ensure that patients with chronic illnesses could have access to drugs that could relieve pain, and that, “for many families, biosimilars could potentially mean financial relief.” However, Dr. Lawson says, the extent of any financial benefit remains to be seen.

SCRS Background
Dr. Lawson has been active with the SCRS since 1979, when he founded the Piedmont Arthritis Clinic, a four-physician private practice serving upstate South Carolina, western North Carolina and northern Georgia. Through its membership in the ACR’s Affiliate Society Council, the SCRS has access to myriad other resources, such as practice management programs; information on state and federal legislation; and yearly presentations from certified professional coders. These services—along others such as with model bylaw assistance, and access resources including ACR templates for drug safety, Medicare, insurance and patient documentation—are provided free of charge to Affiliate Society Council members.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 | Single Page

Filed Under: Legislation & Advocacy, Professional Topics Tagged With: Biologics Price Competition and Innovation Act of 2009, biosimilars substitution bill, H.B. 3438, South Carolina Rheumatism Society

You Might Also Like:
  • ACR Advocacy at the State Level in 2016
  • The ACR’s Advocacy at State Legislature Level in 2016 Focuses on Biosimilars, Step Therapy
  • New Life for the Michigan Rheumatism Society
  • Meet Chris Adams, MD, the New Chair of the ACR’s Affiliate Society Council

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.